Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by N. Wagner-Bartak
Combination of Ibrutinib With Rituximab (Ir) Is Highly Effective in Previously Untreated Elderly (>65 Years) Patients (Pts) With Mantle Cell Lymphoma (Mcl) - Phase Ii Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
British Journal of Haematology
Hematology
A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT-NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Improved Outcome for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) Who Stop Ibrutinib +/− Rituximab for Reasons Other Than Progression of Disease
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Long-Term Outcomes and Mutation Profiling of Patients With Mantle Cell Lymphoma (MCL) Who Discontinued Ibrutinib
British Journal of Haematology
Hematology
Sakk 35/15: A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Combination of Chidamide With Choep Regimen in Previously Untreated Patients With Peripheral T-Cell Lymphoma: A Prospective, Multicenter, Single-Arm, Phase 1b/2 Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
Cancer
Cancer Research
Oncology
Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
A Phase II Study of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Indolent Non-Hodgkin's Lymphoma
British Journal of Haematology
Hematology
